Beyond exon 2--the developing story of RAS mutations in colorectal cancer. Berlin J (2013) N Engl J Med 369: 1059-60 Chemotherapy and immunotherapy in metastatic colorectal cancer. Pohlmann PR, Mernaugh RL, Goff LW (2009) N Engl J Med 360: 2134; author reply 2135-6 Structure and dynamics of AMPA receptor GluA2 in resting, pre-open, and desensitized states. Dürr KL, Chen L, Stein RA, De Zorzi R, Folea IM, Walz T, Mchaourab HS, Gouaux E (2014) Cell 158: 778-792 Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Wei J, Blum S, Unger M, Jarmy G, Lamparter M, Geishauser A, Vlastos GA, Chan G, Fischer KD, Rattat D, Debatin KM, Hatzopoulos AK, Beltinger C (2004) Cancer Cell 5: 477-88 Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ (1997) Nat Med 3: 1233-41 Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) J Clin Oncol 21: 2059-69 Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) J Clin Oncol 20: 3270-5 Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB (2000) J Clin Oncol 18: 3384-9 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) J Clin Oncol 23: 3502-8 Leukemia inhibitory factor upregulates cytokine expression by a murine stromal cell line enabling the maintenance of highly enriched competitive repopulating stem cells. Szilvassy SJ, Weller KP, Lin W, Sharma AK, Ho AS, Tsukamoto A, Hoffman R, Leiby KR, Gearing DP (1996) Blood 87: 4618-28 Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line. Kingsnorth AN, Russell WE, McCann PP, Diekema KA, Malt RA (1983) Cancer Res 43: 4035-8 Aflibercept. Ciombor KK, Berlin J, Chan E (2013) Clin Cancer Res 19: 1920-5 Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW (2006) Clin Cancer Res 12: 1897-905 A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA (2013) Clin Cancer Res 19: 258-67 Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M (2000) Clin Cancer Res 6: 3442-50 A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh YC, Miller LL (2001) Ann Oncol 12: 1575-80 Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Harris RC, Washington MK, Wilson KT, Beauchamp RD, Singh AB (2011) Oncogene 30: 3234-47 Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM (2003) Int J Cancer 104: 496-503 Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. Karron RA, Wright PF, Crowe JE, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR (1997) J Infect Dis 176: 1428-36 Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov VS, Zaika AI (2010) Mol Cancer Ther 9: 693-705 One-year follow-up results of combined mitomycin C trabeculectomy and extracapsular cataract extraction. Joos KM, Bueche MJ, Palmberg PF, Feuer WJ, Grajewski AL (1995) Ophthalmology 102: 76-83 E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW (1997) Mol Cell Biol 17: 1049-56 A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA (2001) Cancer 92: 279-86 A randomized Phase II trial in patients with carcinoma of an unknown primary site. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR (2001) Cancer 91: 592-7 Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA (2004) Cancer 100: 2347-54 Identification of novel germline polymorphisms governing capecitabine sensitivity. O'Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ, Dolan ME (2012) Cancer 118: 4063-73 Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Zhang B, Zhang B, Chen X, Bae S, Singh K, Washington MK, Datta PK (2014) Br J Cancer 110: 946-57 Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Ajani JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P (1995) Eur J Cancer 31A: 665-70 Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Swisher SG, Ajani JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA (2003) Int J Radiat Oncol Biol Phys 57: 120-7 Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R (2004) Int J Radiat Oncol Biol Phys 60: 1484-93 Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R (2004) Int J Radiat Oncol Biol Phys 60: 427-36 Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B (2007) Int J Radiat Oncol Biol Phys 67: 397-404 Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells. Novitskiy SV, Csiki I, Huang Y, Johnson DH, Harth EM, Carbone DP, Dikov MM (2010) J Thorac Oncol 5: 1410-5 Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells. Short SP, Thompson JJ, Bilotta AJ, Chen X, Revetta FL, Washington MK, Williams CS (2019) Mol Cancer Res 17: 882-894 Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. Nicholson B, Paul D, Shyr Y, Garrett M, Hande KR, Johnson DH (1997) Semin Oncol 24: S11-20-S11-23 Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Johnson DH, Paul D, Hande KR (1997) Semin Oncol 24: S22-5 Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy. Grosh WW, Jones HW, Burnett LS, Greco FA (1986) Gynecol Oncol 25: 334-9 Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R, Nakagawa H, Asaoka Y, Kondo Y, Yamashiki N, Goto T, Shiina S, Omata M, Yoshida H, Koike K (2012) J Gastroenterol 47: 1152-9 A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Blanke CD, Stipanov M, Morrow J, Rothenberg M, Chinery R, Shyr Y, Coffey R, Johnson DH, Leach SD, Beauchamp RD (2001) Invest New Drugs 19: 21-7 Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML (2012) Invest New Drugs 30: 290-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.